07:00 , Mar 26, 2012 |  BC Week In Review  |  Clinical News

BVT: Completed Phase II enrollment

CRO Ergomed completed enrollment of 120 patients in a Phase II trial evaluating oral BVT.115959. CBT Development, a virtual company between venture investors Avlar BioVentures and Excalibur Fund Managers, partnered with Ergomed last year to...
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

Ergomed Group deal

CBT Development Ltd. , a virtual company between venture investors Avlar BioVentures Ltd. (Cambridge, U.K.) and Excalibur Fund Managers Ltd. (Cambridge, U.K.), and CRO Ergomed partnered to co-develop CBT's neuropathic pain candidate BVT.115959 . The...
07:00 , May 17, 2010 |  BioCentury  |  Emerging Company Profile

Crescendo: Best of Both Fragments

Crescendo Biologics Ltd. believes its transgenic mouse antibody fragment technology combines the best characteristics of the two leading antibody fragment platforms - human origin and in vivo maturation - which should allow rapid creation of...
07:00 , Oct 12, 2009 |  BioCentury  |  Finance

Ebb & Flow

Facet Biotech Corp. (NASDAQ:FACT) executives seem confident that investors aren't going to take the bait on the $14.50 per share tender offer from Biogen Idec Inc. (NASDAQ:BIIB) - and they cite the company's stock price...
07:00 , May 4, 2009 |  BC Week In Review  |  Company News

Alizyme board of directors update

Alizyme plc (LSE:AZM), Cambridge, U.K.   Business: Gastrointestinal, Endocrine   Retiring: Brian Richards as chairman, effective July 24; Alan Goodman, CEO of Avlar BioVentures Ltd., joined the board and is expected to replace Goodman  ...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Company News

Paradigm Thera, Takeda Pharmaceuticals Co. Ltd. deal

Takeda will acquire Paradigm for undisclosed terms. The deal gives Takeda target identification and medicinal chemistry capabilities in pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity. Takeda's core therapeutic focus areas include...
07:00 , Mar 19, 2007 |  BioCentury  |  Finance

Ebb & Flow

Two new companies, Tragara Pharmaceuticals and Epiphany Biosciences , landed large series A rounds last week. Each was formed around recently in-licensed compounds and hopes to get to a major value inflection point, Phase IIb...
23:56 , Mar 12, 2007 |  BC Extra  |  Company News

Takeda acquiring Paradigm

Takeda (Tokyo:4502) will acquire metabolic, neurology and cancer company Paradigm ( Cambridge , U.K.). Terms of the deal were not disclosed. Paradigm's PTD 634, a small molecule, oral gonadotropin-releasing hormone (GnRH) antagonist, is in preclinical...
00:40 , Jul 8, 2006 |  BC Extra  |  Financial News

Paradigm raises L7 million

Metabolic, neurology and cancer company Paradigm ( Cambridge , U.K.) raised L7 million ($12.9 million) in a series D round. Existing investors Avlar BioVentures; BioOne Capital; Merlin Biosciences; and Lloyds TSB Development Capital participated in...
07:00 , Jun 12, 2006 |  BioCentury  |  Strategy

Engineering its engine

By choosing to merge, Amura Ltd. has broadened its capabilities beyond the protease space originally targeted by its small molecule medicinal chemistry platform, while Proteom Ltd. and its in silico screening and drug design technology...